Date de publication: 4 avril 2017
Promoteur – Intermédiaire Financier
GRIFOLS SALieu
Description
Financing the promoter's R&D programme for new plasma proteins for various therapeutic areas, including Alzheimer's disease, liver cirrhosis, diabetes and cystic fibrosis.
Objectifs
The project covers all stages of development i.e. pre-clinical development as well as clinical development of new health treatments. The project will be managed from the company's headquarters in Barcelona, Spain.
Secteur(s)
- Industrie - Industrie manufacturière
Montant BEI envisagé (montant approximatif)
EUR 170 million
Coût total (montant approximatif)
EUR 502 million
Aspects environnementaux
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Statut
Signé - 5/12/2017